Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2002
Issue release date: May–June 2002 (September 2002)
Section title: Research Article
Tumor Biol 2002;23:179–184
(DOI:10.1159/000064034)

Differential Expression and Activity Status of MMP-1, MMP-2 and MMP-9 in Tumor and Stromal Cells of Squamous Cell Carcinomas of the Lung

Schütz A.a · Schneidenbach D.a · Aust G.b · Tannapfel A.a · Steinert M.c · Wittekind C.a
aInstitute of Pathology, bInstitute of Anatomy and cDepartment for Surgery, University of Leipzig, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: 3/5/2002
Accepted: 6/26/2002
Published online: 9/5/2002
Issue release date: May–June 2002 (September 2002)

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

Matrix metalloproteinases (MMPs) play a key role in cancer progression. Interstitial collagenase (MMP-1) and type IV collagenases (MMP-2, MMP-9) are involved in the initial breakdown of collagen and basement membrane components during tumor growth and invasion. Besides tumor cells, fibroblasts are especially involved in MMP production. The aim of this study was to quantify MMP-1, MMP-2 and MMP-9 within tumor cells and tumor-surrounding fibroblasts compared to normal lung epithelial cells to gain an insight into the function of these MMPs in squamous cell carcinomas of the lung. The expression and activity of MMP-1, MMP-2 and MMP-9 were analyzed in 30 squamous cell carcinomas and in normal lung tissue from the same patients by immunohistology and gelatin zymography. The majority of tumor cells were positive for MMP-1 (mean ± SD: 67.3 ± 26.7%) and MMP-9 (64.7 ± 22.8%), whereas a significantly lower percentage of normal bronchoepithelial cells (47.3 ± 25.4 and 40.3 ± 24.2%, respectively; p < 0.01) and fibroblasts located in the tumor-surrounding tissue (39.7 ± 14.3 and 38.1 ± 24.1%, respectively; p < 0.01) expressed these MMPs. Only a few tumor cells showed any immunoreactivity for MMP-2 (4.4 ± 6.7%), whereas a higher percentage of fibroblasts tested positive for this enzyme (8.6 ± 13.1%; p < 0.01). Using gelatin zymography, we could demonstrate that MMP-2 is activated in the tumor only, not in normal lung tissue. The coordinated expression of MMP-1, MMP-2 and MMP-9 in tumor cells and/or their induction in tumor-surrounding fibroblasts and further activation in the tumor tissue may be involved in the high invasive and metastatic potential of squamous cell carcinomas of the lung. Comparing the results from immunohistology and zymography can give indications for distribution and activity of proteinases, especially certain MMPs such as MMP-2.

© 2002 S. Karger AG, Basel


  

Author Contacts

Professor Ch. Wittekind
Institute of Pathology, University of Leipzig
Liebigstrasse 26, D–04103 Leipzig (Germany)
Tel. +49 341 971 50 00, Fax +49 341 971 50 09
E-Mail wittc@medizin.uni-leipzig.de

  

Article Information

Received: Received: March 5, 2002
Accepted after revision: June 26, 2002
Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 0, Number of References : 30

  

Publication Details

Tumor Biology (Tumor Markers and Translational Cancer Research)
Founded 1980 as ‘Oncodevelopmental Biology and Medicine’ by the ISOBM, continued 1984–1986 as ‘Tumour Biology’
The Journal of the International Society for Oncodevelopmental Biology and Medicine (ISOBM)

Vol. 23, No. 3, Year 2002 (Cover Date: May-June 2002 (Released September 2002))

Journal Editor: T. Stigbrand, Umeå; Managing Editor: P.D. Rye, Oslo
ISSN: 1010–4283 (print), 1423–0380 (Online)

For additional information: http://www.karger.com/journals/tbi


Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: 3/5/2002
Accepted: 6/26/2002
Published online: 9/5/2002
Issue release date: May–June 2002 (September 2002)

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.